Age at Diagnosis and Breast Cancer Survival in Iran

Vostakolaei, Fatemeh Asadzadeh; Broeders, Mireille J. M.; Rostami, Nematollah; Dijck, J.A.A.M. van; Feuth, Ton; Kiemeney, Lambertus A.; Verbeek, A.L.M.

doi:10.1155/2012/517976

Cited by 33 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some findings (Vostakolaei et al, 2012) did not show significant association between survival and age, our results showed otherwise. Patients younger than 40 years old had lower survival compared to patients older than 40 years.…”

Section: Discussioncontrasting

confidence: 90%

Survival Analysis of Breast Cancer Patients in Northwest Iran

Ziaei

Sanaat²,

Asvadi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Breast cancer is the most frequently occurring cancer among Iranian women; however limited studies have been conducted to address survival rates. Objective: The objective was to examine survival rates in Tabriz (Northwest of Iran) and comparing with those of data reported from other cities and countries. Methods: Survival rates were calculated for one, three, five, seven and ten years for 271 breast cancer patients referred to one university clinic during 1997-2008. Results: Survival analysis demonstrated a lower survival rate compared to western countries. Conclusions: Survival rates for our patients are similar/better than other cities in Iran, but lower than certain European countries and the US. Further studies with a higher number of patients are now required.

show abstract

Section: Discussioncontrasting

confidence: 90%

Survival Analysis of Breast Cancer Patients in Northwest Iran

Ziaei

Sanaat²,

Asvadi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…They studied 1500 patients at 6 hospitals in 5 provinces of Iran. The results indicated that the 5-year survival rate was 71% (25). Furthermore, Vahdaninia and Montazeri (2004) measured the total 5-year survival rate to be 62%, while in our study, it was reported to be 85% (26).…”

Section: Discussionsupporting

confidence: 47%

Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival

Hadizadeh

Arani

Olya

2018

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common cancer among women worldwide. It can be categorized into at least 5 main groups, based on antibody markers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which are dissimilar in terms of risk factors, distribution, prognosis, treatment, and clinical outcomes. In this study, we evaluated the survival and therapeutic outcomes of BC using immunohistochemical biomarkers in order to improve disease prognosis and eliminate concerns among women. Methods: The subjects included 1772 women with a diagnosis of BC from January 1999 to January 2014, admitted to Shohada educational hospital and Azar clinic, Tehran, Iran. In this analytical cross sectional study, we selected a simple classification, based on the expression of ER, PR, and HER2. Then, we classified BC patients into 4 subgroups: luminal A (ER+ and/or PR+, HER2-); luminal B (ER+ and/or PR+, HER2+); basal-like (BCL) (ER-, PR-, HER2-); and HER2/neu (ER-, PR-, HER2+) subtypes. In addition, we integrated lymphovascular invasion (LVI) and tumor grade for identifying the groups in terms of HER2 (1+ or 2+ if LVI-was attributed to luminal A or if

show abstract

“…Most of the currently available data indicate that young age is associated with a poor prognosis due to the presence more invasive disease among this population[6, 7, 10–13], which is supported by other studies[8, 9, 14], although some studies have noted that elderly women experience poorer outcomes than younger patients[15, 16]. …”

Section: Introductionmentioning

confidence: 59%

Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database

et al. 2016

View full text Add to dashboard Cite

BackgroundAge is an important risk factor for breast cancer, but data regarding whether patient age at diagnosis is related to breast cancer survival are conflicting. This population-based study evaluated the effect of age on breast cancer prognosis and identified outcome-related factors.Patients and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database and enrolled female primary non-metastatic cases. Patients were subdivided into seven groups, and analyses of the associations between age and overall survival (OS) and breast cancer-specific survival (BCSS) were carried out using the Kaplan-Meier method and Cox regression model, respectively. We also assessed differences in survival among three specific age groups, using the ages of 30 and 50 years as cut-offs. Stratified analyses regarding race, histology, grade, stage and hormone receptor status were also carried out.ResultsA total of 133,057 female patients diagnosed with breast cancer from 2004 to 2008 were included in the current study (6.4% <40 years), Women aged 40 to 49 years and 60 to 69 years exhibited significantly better OS and BCSS, respectively (log-rank, p<0.001), than their counterparts in other groups. Middle-aged women exhibited distinctly better OS (log-rank, p<0.001) and BCSS (log-rank, p<0.001) than their counterparts in the other two age groups. Following adjustments for potential confounding factors, middle-age at breast cancer diagnosis was shown to be an independent predictor of favourable outcomes in terms of OS, but not BCSS (for OS, HR, 0.92; 95%CI, 0.87–0.98; p = 0.007; for BCSS, HR, 0.94; 95%CI, 0.80–1.01; p = 0.075, using the young group as reference). Stratified analysis showed that middle-age was significantly associated with increased survival, except among patients with stage III disease, and that elderly women faced worse prognoses than younger patients.ConclusionOur results indicate that younger breast cancer patients exhibit more aggressive disease than older patients. Middle-aged patients exhibit better OS and BCSS than young and elderly patients but exhibit BCSS rates similar to those of young patients after adjustments for confounders. Stratified analysis demonstrated that middle-aged patients exhibited better survival than young patients, with the exception of patients with stage III disease. An age of 60 years or more was a significant independent predictor of a poor prognosis.

show abstract

Age at Diagnosis and Breast Cancer Survival in Iran

Cited by 33 publications

References 34 publications

Survival Analysis of Breast Cancer Patients in Northwest Iran

Survival Analysis of Breast Cancer Patients in Northwest Iran

Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival

Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database

Contact Info

Product

Resources

About